AVAILABLE MEDICINE FOR Sacubitril,valsartan
There are no products to list.
Introduction to Sacubitril, valsartan
Sacubitril Valsartan is a novel combination therapy aimed at treating heart failure with reduced ejection fraction (HFrEF). This innovative treatment seeks to enhance cardiac function, alleviate symptoms, and decrease the likelihood of hospitalization or mortality related to heart failure. The medication combines two synergistic components: sacubitril, which inhibits neprilysin, and valsartan, an angiotensin II receptor blocker (ARB).
By blocking neprilysin, sacubitril increases levels of beneficial peptides that assist in relaxing blood vessels, minimizing sodium retention, and boosting heart efficiency. On the other hand, valsartan prevents blood vessel constriction by inhibiting the angiotensin II receptor, leading to lower blood pressure. Together, these actions improve the heart's pumping ability and reduce its workload. Research indicates that sacubitril valsartan significantly lowers the risk of cardiovascular death and hospital admissions for heart failure when compared to conventional ACE inhibitors.
Potential side effects include low blood pressure, dizziness, kidney issues, and elevated potassium levels in the blood. Regular monitoring by healthcare professionals is essential for ensuring effective treatment.
This medication is not suitable for individuals with a history of angioedema or those currently taking an ACE inhibitor. Sacubitril valsartan marks a major step forward in managing heart failure and offers patients hope for better health outcomes and enhanced quality of life.
